![]() ![]() ![]() An understanding of the underlying degenerative mechanisms and unraveling the biological mediators of melanocyte loss will open up avenues for testing novel therapeutic approaches in vitiligo management. Several questions remain unsolved which indeed makes vitiligo an excellent model for studying autoimmune and degenerative processes. Depending on the disease course and duration, clinical management primarily involves disease stabilization either by repigmentation or depigmentation of the skin. With the occurrence of vitiligo at any age, most people typically develop it at a young age. Screening methods as such are not available for vitiligo, and the diagnosis is based on the assessment of the absence of melanocytes from the lesions in the affected area. Alteration of genetic factors involved in immune responses and melanogenesis along with environmental factors are central to disease manifestation. It has also been linked with autoimmunity for the cause of melanocyte death in susceptible individuals. ResultsĮmerging evidence underlines the existing connection between deregulated miRNA function and vitiligo pathogenesis. MethodsĪ narrative review of the relevant published literatures known to the authors that comprehensively discussed about vitiligo and its implications was conducted. This review provides an overview of vitiligo, its etiopathogenesis and disease management, and also discusses the scope of network-interaction studies and polypharmacological studies in understanding vitiligo disease module. Vitiligo is a common dermatological disorder of chronic depigmentation which is phenotypically characterized by white macules on the skin caused as a result of the systematic destruction of functional melanocytes. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |